Testing Two Bone-Protecting Drugs in Critically Ill Older Adults
Tests denosumab or zoledronic acid against placebo to protect bone in intensive care patients.
Key facts
- Who runs it
- Australian and New Zealand Intensive Care Research Centre
- Where
- Auckland and Wellington, New ZealandSee the 2 sitesAlso in 1 other country, 20 sites
- Trial code
- Registry title
- Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 450 people, planned
- Started
- 15 Jul 2021
- Expected to end
- 28 Feb 2027
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Denosumab 60 MG/ML
- Zoledronic Acid 5Mg/Bag 100Ml Inj
- Sodium Chloride 0.9% or 5% Dextrose Intravenous
- Sodium Chloride 0.9% Injection
- Record updated
- 4 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 50 or older and men aged 70 or older who are in intensive care and expected to survive the current hospital stay.
- Age
- Women 50 years or older; men 70 years or older.
- Sex
- Women aged 50 or older and men aged 70 or older.
- Disease stage
- In the Intensive Care Unit for 2 or more calendar days, not expected to leave on the second day, and needing ICU-level support for at least 6 hours in total.
- Earlier treatment
- Cannot have recently had bone-protecting treatment, such as a bisphosphonate, strontium or teriparatide in the last 2 years, menopausal hormone therapy or romosozumab in the last 12 months, or denosumab in the last 6 months.
Main reasons for not taking part
- Cancer that has spread to the bones, or multiple myeloma
- Paget's disease, or pregnancy
- Kidney function (eGFR) below 30 ml/min, or receiving renal replacement therapy
- Known reaction to denosumab or zoledronic acid, or dental or gum infection or broken teeth
- Recent fragility fracture of the hip, spine, femur or forearm, or unable to have a bone density scan
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Female age ≥ 50 years or male age ≥ 70 years
- Has been in the Intensive Care Unit for 2 or more calendar days and is not expected to be discharged from the Intensive Care Unit on the second day
- Has required Intensive Care Unit level support (i.e. intravenous vasoactive drugs, or invasive mechanical ventilation, or non-invasive ventilation or high flow nasal oxygen at Fraction inspired Oxygen ≥0.4 and/or gas flows ≥40L/m) for a minimum cumulative duration of 6 hours
- Expected to survive the current hospital admission
Who cannot take part
- Current estimated Glomerular Filtration Rate <30ml/min or receiving renal replacement therapy
- Current treatment with anti-fracture agent (bisphosphonate, strontium or teriparatide within previous 2 years, or menopausal hormone therapy or romosozumab within previous 12-months or denosumab within previous 6 months)
- Cancer related metastatic bone disease or multiple myeloma
- Paget's disease
- Obvious holes in teeth or broken teeth or dental or gum infection
- International Normalised Ratio > 3.0 or Platelet count < 30 10\^9/L
- Pregnancy
- Known contraindication to denosumab or zoledronic acid
- Known untreated hypoparathyroidism
- Current fragility fracture of hip, spine, femur or forearm
- Exceeds weight limit for BMD scan at site or unable to undertake Bone Mineral Density for any reason
This trial is currently available in New Zealand.
Also in 1 other country, 20 sites
- Auckland City HospitalAuckland, New ZealandContact: Shay McGuinnessTaking people
- Wellington Regional HospitalWellington, New ZealandContact: Paul YoungTaking people
About the trial
What the trial wants to find out
The Bone Zone trial is a prospective, multi-centre, double-blind, phase II, randomised controlled trial evaluating the effect of denosumab or zoledronic acid compared to placebo on change in bone mineral density over one year in women aged 50 years or older and men aged 70 years or older requiring admission to intensive care for greater than 24 hours.
Read full original descriptionShow less
450 women aged 50 years or older and men aged 70 years or older, admitted to intensive care for greater than 24 hours will be recruited into the study from participating study centres.
The 3 groups in the trial
- DenosumabExisting treatment, for comparison
Patients allocated to the Denosumab arm will receive Denosumab 60mg in 1ml, administered via subcutaneous injection on Study Days 1 and 180.
Treatment: Denosumab 60 MG/ML and Sodium Chloride 0.9% or 5% Dextrose Intravenous
- Zoledronic acidExisting treatment, for comparison
Patients allocated to the Zoledronic acid arm will receive Zoledronic acid 5mg in 100ml 0.9% Sodium Chloride or 5% Dextrose, administered via intravenous infusion over at least 15 minutes on Study Day 1.
Treatment: Zoledronic Acid 5Mg/Bag 100Ml Inj and Sodium Chloride 0.9% Injection
- PlaceboPlacebo, for comparison
Patients allocated to the placebo arm will receive 0.9% Sodium Chloride 1ml administered via subcutaneous injection on Days 1 and Day 180 and 0.9% Sodium Chloride 100ml or 5% Dextrose administered via intravenous infusion over at least 15 minutes on Day 1.
Treatment: Sodium Chloride 0.9% or 5% Dextrose Intravenous and Sodium Chloride 0.9% Injection
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults - A Randomised Controlled Trial
- Plain-language title
- Testing Two Bone-Protecting Drugs in Critically Ill Older AdultsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 4 March 2026